Annual Meeting

Read the Annual Meeting Abstracts Now

ASGCT Staff - April 28, 2020

Our largest collection of abstracts in Society history is now available online.

Starting today, we are proud to share our collection of abstracts for the ASGCT 23rd Annual Meeting with you. This collection is the largest we've ever had and is full of the field's latest and most innovative science. You can read it online now.

For a preview of some of the presentations to look forward to during our first-ever virtual meeting, you'll find highlights below of the abstract collection, including recipients of the Excellence in Research awards, whose abstracts will be presented as part of the Presidential Symposium and Presentation of the Top Abstracts, as well as the Clinical Trials Spotlight Symposia.

Read the ASGCT 23rd Annual Meeting Abstracts

Presentation of the Top Abstracts

Thursday, May 14, 1:15-3:15 p.m.

905. Generation of Islet-Specific Gene-Edited Regulatory T Cells (edTreg) for Restoration of Immune Tolerance in Type 1 Diabetes
Presented by Peter Cook, Ph.D., Seattle Children’s Research Institute

906. Validation and Long-Term Follow Up of CD33 Off-Targets Predicted In Vitro and In Silico Using Error-Corrected Sequencing in Rhesus Macaques
Presented by Aisha AlJanahi, NIH

907. Chemical Engineering of Therapeutic RNAs for Allele Specific Gene Silencing In Vivo
Presented by Faith Conroy, UMass Medical School

908. Chimeric Antigen Receptor T Cell Therapy and Env Boosting Enables Durable SHIV Remission in Nonhuman Primates
Presented by Blake Rust, Ph.D., Fred Hutchinson Cancer Research Center

Clinical Trials Spotlight Symposia

Friday, May 15, 8-9:45 a.m.

1298. Resolution of Sickle Cell Disease (SCD) Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 HGB-206 Group C Study
Presented by: John F. Tisdale, M.D., NHLBI, National Institutes of Health

1299. First-in-Human Gene Therapy for Tay-Sachs Disease: Report of Two Infants Treated on an Expanded Access Clinical Trial of rAAVrh8-HexA/HexB (AXO-AAV-GM2)
Presented by: Terence R. Flotte, M.D., University of Massachusetts Medical School

1300. Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Two Year Follow-Up Results
Presented by Donald Kohn, M.D. University of California, Los Angeles

1301. Natural Killer T Cells Expressing a GD2-CAR and IL-15 for Children with Neuroblastoma - A First-In-Human Phase 1 Trial
Presented by Andras Heczey, M.D., Baylor College of Medicine

1302. A Phase 2 Trial of MGTA-456 Cell Therapy Demonstrates Rapid and Durable Long-Term Improvement in Disease-Specific Outcomes in Inherited Metabolic Disease (IMD) Patients
Presented by John Wagner, M.D., University of Minnesota

1303. CoupledCARTMTechnology for Treating Thyroid Cancer & 1304. Novel CoupledCARTMTechnology for Treating Colorectal Cancer
Presented by Lei Xiao, Innovative Cellular Therapeutics

Related Articles

Annual Meeting

10 Tips to Submit Your Abstract for the ASGCT Annual Meeting

Phil Tai, PhD - November 13, 2023
Annual Meeting

Last Chance: Submit Your #ASGCT24 Abstracts!

Send your research through Jan. 26, 2024 - November 13, 2023
Annual Meeting

NEW for 2024 Annual Meeting Abstract Submissions: Plain Language Summary

Alison Kujawski, MPH - October 30, 2023
Annual Meeting

Global Speakers Address Developing Gene Therapies in Low- and Middle-Income Countries

Martín Bonamino, Ph.D. - June 03, 2021